Regulatory China’s NMPA approves Akeso’s gumokimab for plaque psoriasis Pharmaceutical Business ReviewThe approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies.Immunology & InflammationRead full story pharminent June 12, 2026 (Last updated: June 19, 2026) Pharmaceutical Business Review The approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Previous PostNext: Novo Nordisk comeback stirs as Wegovy pill wins UK approval Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
